Drug Approval | March 22, 2023
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Proposed combination enhances Pfizer’s position as a leading company in oncology
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights the key company collaborations in pharma to advance AI-powered drug repurposing techniques.
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
Subscribe To Our Newsletter & Stay Updated
